Nrx pharmaceuticals and hungarian health officials agree on pathway for zyesami® and brilife covid-19 vaccine trials

Budapest, hungary, dec. 09, 2021 (globe newswire) -- nrx pharmaceuticals (nasdaq:  nrxp ) today announced the conclusion of high-level meetings in hungary that are expected to lead to utilization of zyesami® (aviptadil) in that country and the pivotal clinical trial of the brilife covid-19 vaccine (brilife).
NRXP Ratings Summary
NRXP Quant Ranking